News | August 25, 2011

Radiation Therapy Oncology Group Awards US Oncology Research Full Member Status

August 25, 2011 — US Oncology Research (USOR) and Radiation Therapy Oncology Group (RTOG) announced that USOR has earned Full Member status. As a Full Member, USOR has proven to be a leader in radiation clinical trials. The organization is one of fewer than 50 to reach this status.

Since becoming an Affiliate Member of RTOG in 2008, USOR quickly became one of the top accruing members. Its network of oncology practices eventually enrolled more patients in RTOG trials than any other member. In 2010, RTOG announced USOR ranked number one in patient accruals, surpassing all affiliate and full RTOG members.

All together, network physicians have enrolled 163 patients into RTOG clinical trials held at community-based oncology practices. This allows patients to receive cutting-edge radiation clinical trials in their hometowns.

"US Oncology Research has been an outstanding Affiliate Member, and we're excited to award the network Full Member status. We at RTOG are very pleased that US Oncology Research achieved full member status as quickly as they did," said Walter J Curran, Jr., M.D., chairman, RTOG group chairman and executive director of the Winship Cancer Institute of Emory University. "Their commitment to providing the infrastructure to accrue large numbers of patients into clinical trial research from community-based practices will not only benefit their patients, it will also help us answer our research questions faster, and that will benefit all cancer patients."

Radiation oncology-focused clinical trials offer cancer patients integrated and unique therapies that can provide a better chance for survival. Clinical trials in cancer care, whether focused on chemotherapy, radiation or other treatment methods, seek improvement upon standard treatment, so each patient has the best opportunity for a positive outcome.

"We are making great strides in a concentration that is quite unique," said Vivek Kavadi, M.D., medical director of radiation oncology for US Oncology and radiation oncologist with Texas Oncology-Sugar Land. "Having radiation oncology clinical trials available in local communities is crucial for our patients. They are able to participate in integrated, radiation-focused clinical trials that are truly state-of-the-art."

There are 19 RTOG approved sites affiliated with USOR. These community-based practices are located across the country and had 91 accruals in 2010. USOR averages eight accruals per month.

In order to remain an RTOG Full Member, the membership evaluation committee, according to the RTOG membership evaluation policy and the group bylaws, must evaluate USOR yearly.

Based in Philadelphia, RTOG is a key clinical research component of the American College of Radiology (ACR) and serves as a multi-institutional, international clinical cooperative group funded primarily by the National Cancer Institute (NCI).

For more information: www.usoncology.com or www.rtog.org

Related Content

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.
Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next
The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

News | Linear Accelerators | January 20, 2021
January 20, 2021 — A joint team of researchers from Radiation Oncology at Dartmouth's and...
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The ...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Myocarditis among recovering COVID-19 athletes less common than previously reported

Getty Images

News | Cardiac Imaging | January 11, 2021
January 11, 2021 — In a letter published in the December issue of the American Heart Association's...
Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound.

Jeff Elias, MD, is a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. Image courtesy of UVA Health

News | Focused Ultrasound Therapy | January 08, 2021
January 8, 2021 — A scalpel-free alternative to brain surgery has the potential to benefit people with...
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of